TYK2 and IL‐23 Pathway Therapies in Psoriasis: Associations With IL‐6, Tryptophan Metabolism, and Depressive Symptoms
International Journal of Dermatology · 2026
DOI: 10.1111/ijd.70230 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Dermatology, 2026. Verfasst von Lanmei Lin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Huashan Hospital Affiliated with Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Psoriasis, TYK2 Kinase, Depression, Tryptophan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.
Themen: Depression
Abstract (Originalsprache)
Background
Psoriasis and depression frequently coexist, creating a complex, bidirectional relationship that complicates treatment. This study, integrating clinical assessments with transcriptomic and metabolomic analyses, hypothesizes that TYK2 (tyrosine kinase 2) inhibitors possess a dual therapeutic potential to simultaneously address both dermatological manifestations of psoriasis and the frequently accompanied depressive symptoms.
Methods
In a cohort of 298 psoriasis patients evaluated using the Hospital Anxiety and Depression Scale (HADS), participants were categorized into a TYK2 inhibitor group, a Janus kinase (JAK) inhibitor group, and a non‐JAK pool (comprising interleukin [IL]‐23 biologics, IL‐17 biologics, and other treatments) to avoid overlapping JAK pathway inhibition. Statistical analysis was conducted using generalized linear models (GENMOD), with adjustments for the following covariates: age, sex, Psoriasis Area and Severity Index (PASI), body surface area (BSA), prior systemic or biologic therapy within 12 months, disease duration, and phototherapy history.
Results
For HADS‐D scores, the TYK2 inhibitor group showed significantly lower values compared with the non‐JAK pool ( β = 1.23, 95% confidence interval [CI]: 0.37–2.10). However, no significant differences were observed when compared with the IL‐23 biologics group ( β = 0.67, 95% CI: −0.76–2.10) or the JAK inhibitor group ( β = 0.84, 95% CI: −1.54–3.21). Transcriptomic analysis of peripheral blood revealed significant downregulation of genes related to the IL‐6 receptor, long‐term depression pathways, and Th17 cell differentiation, while pathways associated with neuronal activity were upregulated. Metabolomic profiling highlighted a decrease in kynurenic acid, which is known for its pro‐inflammatory and depressive effects, and an increase in 1H‐indole‐3‐propanoic acid, an anti‐inflammatory metabolite with neuroprotective properties. It is important to note that these findings are based on exploratory omics analyses, for which false discovery rate (FDR) control was applied.
Conclusions
These findings provide a hypothesis that TYK2 inhibitors disrupt the persistent “peripheral inflammation–central depression” cycle by targeting the IL‐23/Th17 axis and modulating the IL‐6/tryptophan metabolic hub. This innovative, multi‐targeted approach represents a possibility for treating psoriasis with comorbid depression, offering not only clinical improvements in both skin and mood symptoms but also enhanced patient adherence to treatment regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Huashan Hospital Affiliated with Fudan University, Shanghai, China.
- Clinical Research Unit, Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
- Institute of Neurology, Huashan Hospital Affiliated with Fudan University, Shanghai, China.
- Department of Nursing, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Dermatology, General Hospital of Ningxia Medical University, Yinchuan, China.
ORCID-Profile: Yilun Wang, Kexiang Yan
Förderung
- National Key Research and Development Program of China
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
- Clinical Research Plan of SHDC
Zitieren
APA
Lin, L., Dong, C., Wu, G., Zhu, X., Liang, X., Zhu, J., Huang, H., Wang, Y., Sun, J., Zheng, C., Yan, K., Lu, X., Tian, B., Yu, N., Xu, J., & Du, J. (2026). TYK2 and IL‐23 Pathway Therapies in Psoriasis: Associations With IL‐6, Tryptophan Metabolism, and Depressive Symptoms. International Journal of Dermatology. https://doi.org/10.1111/ijd.70230
Vancouver
Lin L, Dong C, Wu G, Zhu X, Liang X, Zhu J, et al. TYK2 and IL‐23 Pathway Therapies in Psoriasis: Associations With IL‐6, Tryptophan Metabolism, and Depressive Symptoms. International Journal of Dermatology. 2026. doi:10.1111/ijd.70230
BibTeX
@article{Lin2026,
author = {Lin, Lanmei and Dong, Canbin and Wu, Gujie and Zhu, Xinyi and Liang, Xiaoniu and Zhu, Junhao and Huang, Huiyu and Wang, Yilun and Sun, Jiazheng and Zheng, Chenghui and Yan, Kexiang and Lu, Xiaonian and Tian, Bingjie and Yu, Nan and Xu, Jinhua and Du, Juan},
title = {TYK2 and IL‐23 Pathway Therapies in Psoriasis: Associations With IL‐6, Tryptophan Metabolism, and Depressive Symptoms},
journal = {International Journal of Dermatology},
year = {2026},
doi = {10.1111/ijd.70230}
}
EUVIMED